Skip to main content
SpringerLink
Log in

Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Bischoff H, Angerbauer R, Boberg M, et al. Preclinical review of cerivastatin sodium — a step forward in HMG-CoA reductase inhibition. Atherosclerosis 1998; 139Suppl. 1: S7–13

    Article  PubMed  CAS  Google Scholar 

  2. Davignon J, Hanefeld M, Nakaya N, et al. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/HI studies. Am J Cardiol 1998; 82(4B): 32J–39J

    Article  PubMed  CAS  Google Scholar 

  3. Stein E. Cerivastatin in primary hyperlipidemia — a multicenter analysis of efficacy and safety. Atherosclerosis 1998; 139Suppl. 1: S15–22

    Article  PubMed  CAS  Google Scholar 

  4. Kuhlmann J, Mück W, Bischoff H, et al. Cerivastatin (BAY w 6228): a novel HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 1998; 16(3): 236–63

    Article  CAS  Google Scholar 

  5. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21(6-22): S12–23

    CAS  Google Scholar 

  6. Oo C, Akbari B, Lee S, et al. Lack of effect of orlistat on the pharmacokinetics and pharmacodynamcis of pravastatin. Clin Pharmacol Ther 1999; 65(2): 187

    Article  Google Scholar 

  7. Quion JA, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27(2): 94–103

    Article  PubMed  CAS  Google Scholar 

  8. Mück W, Ochmann K, Rohde G, et al. Influence of erythro-mycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998; 53: 469–73

    Article  PubMed  Google Scholar 

  9. Krol GJ, Beck GW, Ritter W, et al. LC separation and induced fluorimetric detection of rivastatin in blood plasma. J Pharm Biomed Anal 1993; 11: 1269–75

    Article  PubMed  CAS  Google Scholar 

  10. Steinjans VW, Hartmann M, Huber R, et al. Lack of pharmaco-kinetic interaction as an equivalence problem. J Clin Pharmacol Ther 1991; 29: 323–8

    Google Scholar 

  11. European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit. CPMP Note for guidance on the investigation of drug interactions: CPMP/EWP/560/95. London: EMEA, Jun 1998

    Google Scholar 

  12. Pan HY, DeVault AR, Brescia A, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol 1993; 31(6): 291–4

    CAS  Google Scholar 

  13. Mück W, Ochmann K, Mazzu A, et al. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor. Int J Clin Res 1999; 27(3): 20–7

    Google Scholar 

Download references

Acknowledgements

This study was sponsored by Bayer AG, Germany. We thank the medical and laboratory team conducting the study for their skilled technical assistance.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Bayer AG, Pharma Research Center, Aprather Weg, Building 470, D-42096, Wuppertal, Germany

    Wolfgang Mück, Holger-Georg Adelmann, Thorsten Ruf, Sigrun Linger & Barbara Voith

Authors
  1. Wolfgang Mück
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holger-Georg Adelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thorsten Ruf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sigrun Linger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Barbara Voith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Mück.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mück, W., Adelmann, HG., Ruf, T. et al. Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin. Clin. Drug Investig. 19, 71–73 (2000). https://doi.org/10.2165/00044011-200019010-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200019010-00009

Keywords

Search

Navigation